PROCEPT BioRobotics Corp. (PRCT, Financial) has reported a robust start to the year, announcing first-quarter revenues of $69.2 million. This performance exceeded market expectations of $65.4 million, marking a significant 55% increase from the same period last year.
The company's Chief Executive Officer emphasized that the procedural momentum experienced at the beginning of 2025 indicates that previous challenges have been surmounted, positioning the company for continued strong growth this year. The successful launch of the Hydros system in the United States has contributed significantly to this growth, particularly with large strategic Integrated Delivery Networks (IDNs).
During the first quarter, corporate IDN multi-unit orders represented around 45% of U.S. system placements, underscoring that Aquablation(R) therapy is gaining traction as a strategic priority among prominent health systems.
